Federal Rescheduling Could Free $3B+ Locked in Cannabis Tax Penalties

The Drug Enforcement Administration's decision to reschedule cannabis from Schedule I to Schedule III has set in motion what industry analysts are calling the largest tax correction in U.S. cannabis history—one that could unlock billions in previously unreported profits.

For nearly a decade, federally legal cannabis operators have been subject to Internal Revenue Code Section 280E, a Reagan-era provision originally designed to prevent drug traffickers from writing off business expenses. The result: effective tax rates often exceeding 70% for profitable cannabis companies, compared to the standard 21% corporate rate.

"We've been operating with one hand tied behind our backs," said Andrew Kline, policy director at the National Cannabis Roundtable, in a statement following the DEA's announcement. "280E has artificially depressed reported earnings across the entire sector for years."

The Numbers Tell the Story

Industry financial data reveals the scale of the distortion. Multi-state operators like Curaleaf and Trulieve have reported effective tax rates between 60% and 80% in recent quarters—rates that would bankrupt most conventional businesses. Green Thumb Industries paid $171 million in federal taxes in 2023 on $378 million in pre-tax income, an effective rate of 45%.

But those figures don't capture the full picture. Because 280E prohibits standard business deductions—rent, salaries, marketing, everything except cost of goods sold—cannabis companies' reported profit margins have been systematically understated.

Financial analysts at Viridian Capital Advisors estimate that Schedule III status could improve industry-wide EBITDA margins by 10 to 15 percentage points once full deductibility takes effect. For the top 15 publicly traded cannabis companies alone, that translates to roughly $800 million in annual tax savings.

Across the broader $30 billion U.S. cannabis market, the total impact could exceed $3 billion annually.

What Happens Next

The rescheduling process isn't complete. The DEA's proposal now enters a public comment period, followed by final administrative review. Legal experts expect the change to take effect in early 2027, though some companies are already adjusting their accounting practices in anticipation.

"The first quarter after 280E relief kicks in, we're going to see some eye-popping earnings reports," said Emily Paxhia, managing partner at Poseidon Investment Management. "Companies that looked marginally profitable will suddenly show their true economics."

But the transition won't be simple. The IRS has provided limited guidance on how companies should handle the changeover, and tax attorneys are already debating whether businesses can retroactively claim deductions from previous years. Some firms have preserved detailed expense records specifically for this possibility, though the legal pathway remains unclear.

The Banking Question

While Schedule III eliminates 280E, it doesn't automatically solve cannabis banking restrictions. The Secure and Fair Enforcement (SAFE) Banking Act—which would provide explicit protections for financial institutions serving cannabis clients—remains stalled in Congress.

Still, tax normalization removes one of the industry's most punishing competitive disadvantages. Cannabis operators will finally be able to deduct ordinary business expenses like any other legal enterprise, from employee health insurance to equipment depreciation.

For investors who've watched cannabis stocks struggle for years despite growing revenues, the rescheduling decision offers a stark reframing: maybe the problem wasn't the business model. Maybe it was the tax code.

The public comment period on DEA's rescheduling proposal closes July 15, 2026. Industry groups are preparing detailed submissions supporting the change, while some law enforcement organizations have signaled opposition to any relaxation of cannabis controls.

---

This article is based on original reporting by www.forbes.com.